NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Credit: GlobeNewswire
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer ('NSCLC”) amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses obs...